Pfizer says its experimental antiviral pill cuts risk of severe COVID-19 by 89%

Reuters
@Reuters

BREAKING: Pfizer says its experimental antiviral pill cuts risk of severe COVID-19 by 89% reut.rs/3o0RGRF
Source: Reuters on Twitter, 5/11/2021

 

Nov 5 (Reuters) – A trial of Pfizer Inc’s (PFE.N) experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease, the company said on Friday.

 

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company.

The Company is engaged in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products. Its global portfolio includes medicines and vaccines.

The Company works across markets to develop wellness, prevention, treatments and cures. It collaborates with healthcare providers, governments and local communities to support and provide access to healthcare.

Its medicines and vaccines provide value for healthcare providers and patients, through treatment of diseases, improvements in health, wellness.

It sells its prescription pharmaceutical products to wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. In the United States, it sells its vaccines products to the federal government, centers for disease control and prevention (CDC), wholesalers, individual provider offices, retail pharmacies and integrated delivery networks.

Source: Reuters

Last Updated on 05.11.2021 by iskova

Добавить комментарий